On June 30, AbbVie announced its intention to acquire Capstan Therapeutics in a deal valued at up to $2.1 billion in cash.

AbbVie said on Monday it would acquire privately held cell therapy developer Capstan Therapeutics in a deal worth up to $2.1 ...

AbbVie Inc. (NYSE:ABBV) is one of the best high growth stocks. On June 30, Morgan Stanley maintained an Overweight rating and ...

AbbVie is on board with the idea. The Big Pharma will pay up to $2.1 billion in cash at closing to acquire Capstan. In return ...

AbbVie announced it will acquire Capstan Therapeutics, a startup developing CAR-T therapies for autoimmune conditions, ...

AbbVie’s $2.1 billion acquisition of Capstan Therapeutics aims to advance in vivo CAR-T therapies, transforming autoimmune ...

AbbVie has entered into a $1 billion licensing agreement with IGI Therapeutics SA, for IGI's lead investigational drug for ...

The acquisition will expand AbbVie's exploration of in vivo CAR-T therapy, an ambitious approach that could sidestep some of ...

AbbVie gains control of an in vivo CAR-T therapy that could overcome limitations with currently approved autologous ...

AbbVie has agreed to buy Capstan Therapeutics for up to $2.1 billion, expanding its pipeline with a potential first-in-class ...

Capstan Therapeutics Inc. is a clinical-stage biotechnology company that specializes in developing CAR-T therapies. These therapies use a patient’s immune cells, specifically T-cells, to combat ...